Abstract
The endothelin-A-receptor antagonist ZD4054 can improve overall survival (OS) in patients with pain-free or mildly symptomatic hormone-refractory prostate cancer (HRPC) who have bone metastases. In a double-blind phase II trial, Nick James (Birmingham, UK) and co-workers randomly assigned 312 patients in a 1:1:1 ratio to two different doses of ZD4054 or to placebo. No significant difference in progression-free survival (PFS) between treatment groups was noted. However, patients assigned ZD4054 has significantly improved OS compared with those assigned placebo (23·5 and 24·5 months vs 17·3 months). The hazard ratio (HR) versus placebo for patients assigned the higher dose of ZD4054 was 0·65 (95% CI 0·49–0·86; p=0·052) and the corresponding HR for the low-dose group was 0·55 (0·41–0·73; p=0·008). Headaches, peripheral oedema, and nasal congestion occurred in more than 30% of patients assigned ZD4054.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
